Amisulpride: A review of its use in the management of schizophrenia

Drugs

Volumn 61, Issue 14, 2001, Pages 2123-2150

  Curran, M P ^a   Perry, C M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; AMISULPRIDE; APOMORPHINE; BENZAMIDE DERIVATIVE; CLOZAPINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; FLUPENTIXOL; HALOPERIDOL; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; REMOXIPRIDE; RISPERIDONE;

CLINICAL TRIAL; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG OVERDOSE; DRUG RECEPTOR BINDING; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MENTAL DISEASE; MULTICENTER STUDY; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; QUALITY OF LIFE; RECEPTOR OCCUPANCY; REVIEW; SCHIZOPHRENIA;

EID: 0035214352     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200161140-00014     Document Type: Review

References (116)

1. Amisulpride: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of schizophrenia
2. Amisulpride: From animal pharmacology to therapeutic action
3. 3 dopamine receptor antagonist activity and limbic selectivity
4. 3 receptor antagonist with both presynaptic and limbic selectivity
5. From pharmacological profiles to clinical outcomes
6. Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding
7. 2 receptor occupancy in relation to clozapine serum concentration; a PET study of schizophrenic patients
8. Effects of amisulpride, an atypical antipsychotic which blocks preferentially presynaptic dopamine autoreceptors, on integrated functional cerebral activity in the rat
9. Potentiation by low doses of selected neuroleptics of food-induced conditioned place preference in rats
10. 3 receptor antagonist on the electrical activity of midbrain dopaminergic neurons
11. 2 receptor occupancy by amisulpride in schizophrenia
12. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: Relation to extrapyramidal side effects
13. Positron emission tomography studies on dopamine receptors in schizophrenia
14. 2 dopamine receptor blockade by amisulpride in schizophrenia
15. 2A receptors: A PET study of chlorpromazine, clozapine, and amisulpride in schizophrenic patients
16. Cognitive impairment in schizophrenia: Its impact on social functioning
17. The effect of neuroleptics on cognitive and psychomotor function
18. The effects of neuroleptics on neuropsychological test results of schizophrenics
19. Guidelines for the use of antipsychotic drugs in healthy volunteers
20. Lack of interaction between amisulpride and lorazepam on psychomotor performance and memory in healthy volunteers
21. Psychomotor, cognitive, extrapyramidal, and affective functions of healthy volunteers during treatment with an atypical (amisulpride) and a classic (haloperidol) antipsychotic
22. Single oral doses of amisulpride do not enhance the effects of alcohol on the performance and memory of healthy subjects
23. Effects of haloperidol and amisulpride on motor and cognitive skill learning in healthy volunteers
24. The acute effects of amisulpride (50 mg and 200 mg) and haloperidol (2 mg) on cognitive function in healthy elderly volunteers
25. Effects of 50mg amisulpride on EEG, psychomotor and cognitive functions in healthy sleep-deprived subjects
26. Atypical antipsychotics and memory function in patients with chronic schizophrenia
27. Safety and pharmacokinetics of a single oral dose of amisulpride in healthy elderly volunteers
28. 2-like receptors by amisulpride: Effects on hormone secretion in healthy volunteers
29. Amisulpride: A review of its clinical potential in dysthymia
30. Pharmacokinetics and metabolism of amisulpride
31. A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers
32. Amisulpride pharmacokinetics: No difference between young and elderly subjects
33. Amisulpride: Kinetics in patients with renal failure
34. Amisulpride does not inhibit cytochrome P450 isozymes
35. No effect of amisulpride on lithium pharmacokinetics
36. Treatment of schizophrenia 1999
37. Schizophrenia: Its etiology and impact
38. The diagnosis and understanding of schizophrenia. Part III. Speculations on the processes that underlie schizophrenic symptoms and signs
39. Practice guideline for the treatment of patients with schizophrenia
40. Deficit and non-deficit forms of schizophrenia: The concept
41. A comparative double-blind trial of amisulpride versus haloperidol in the treatment of acute psychotic disorders
42. A double blind, controlled, multicenter trial of amisulpride versus high dose haloperidol in acute psychotic disorders
43. Amisulpride, an atypical antipsychotic, in the treatment of acute episodes of schizophrenia: A dose-ranging study vs haloperidol
44. Amisulpride versus haloperidol in treatment of schizophrenic patients: Results of a double-blind study
45. Improvement of acute exacerbations of schizophrenia with amisulpride: A comparison with haloperidol
46. 2like antagonist
47. Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia
48. Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: Results of a multicentre, double-blind study
49. Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia
50. Rating scales in schizophrenia: A review of their usefulness for assessing atypical antipsychotics
51. Amisulpride improves affective symptoms in acute schizophrenia
52. Clinical advantages of amisulpride in the treatment of acute schizophrenia
53. Amisulpride versus risperidone in schizophrenia: Comparing clinical and functional outcome in a 6 month study
54. Evaluation of efficacy and safety of amisulpride in the treatment of schizophrenia
55. Negative symptoms in schizophrenia: Considerations for clinical trials
56. Assessing the efficacy of treatments for the deficit syndrome of schizophrenia
57. Psychopathology and common sense: Where we went wrong with negative symptoms
58. Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia
59. Treatment of negative symptoms in schizophrenia with amisulpride
60. Improvement of some schizophrenic deficit symptoms with low doses of amisulpride
61. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride
62. A double blind, controlled, multicenter trial of low dose amisulpride (Solian 50) versus low dose fluphenazine in the treatment of negative symptoms in chronic schizophrenia
63. Clinical, EEG mapping and psychometric studies in negative schizophrenia: Comparative trials with amisulpride and fluphenazine
64. One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms. Amisulpride v. haloperidol
65. Adjunctive fluoxetine or amisulpride improves schizophrenic negative symptoms
66. Safety of amisulpride (Solian): A review of 11 clinical studies
67. Atypical antipsychotics and weight gain - A systematic review
68. Bodyweight gain associated with atypical antipsychotics: Epidemiological and therapeutic implications
69. Tolerability of atypical antipsychotics
70. Effects of newer atypical antipsychotics on autonomic neurocardiac function: A comparison between amisulpride, olanzapine, sertindole, and clozapine
71. The costs of schizophrenia. Assessing the burden
72. Some aspects of the cost of schizophrenia in France
73. Costs of schizophrenia in the Netherlands
74. Economics and schizophrenia: The real cost
75. Health care expenditure on schizophrenia patients in Belgium
76. Costs of services for schizophrenic patients in Norway
77. Costs of schizophrenia
78. The hidden costs of schizophrenia
79. Economic assessment of neuroleptic strategies in schizophrenia
80. Impact of amisulpride on health care resources in schizophrenia; intermediate results of OASIS study
81. A comparison of resources utilization in schizophrenia: Amisulpride versus risperidone
82. Switching approach in the management of schizophrenia patients
83. Switching to amisulpride: Findings from a retrospective questionnaire
84. Managing schizophrenia: Interventions and outcomes
85. Measuring the effect of treatment on quality of life in patients with schizophrenia: Focus on utility-based measures
86. Late-onset schizophrenia: Epidemiology, diagnosis, management and outcomes
87. Schizophrenia in the elderly: Guidelines for management
88. Conventional antipsychotic medications for schizophrenia
89. Treatment outcomes in schizophrenia: Implications for practice, policy, and research
90. Drug treatments for schizophrenia
91. Evaluating the effects of antipsychotics on cognition in schizophrenia
92. Role of newer atypical antipsychotics in the management of treatment-resistant schizophrenia
93. Psychopharmacologic treatment of negative schizophrenic symptoms
94. Do negative symptoms respond to pharmacological treatment?
95. A comparative review of new antipsychotics
96. Biotransformation of post-clozapine antipsychotics: Pharmacological implications
97. Conventional and newer neuroleptics in the treatment of schizophrenia spectrum disorders
98. Efficacy and safety of novel antipsychotics: A critical review
99. Atypical antipsychotics in the treatment of schizophrenia: Systematic overview and meta-regression analysis
100. New antipsychotic agents: Emerging clinical profiles
101. Newer antipsychotics
102. Novel antipsychotics, extrapyramidal side effects and tardive dyskinesia
103. Atypical neuroleptics
104. The new antipsychotics, and their potential for early intervention in schizophrenia
105. Atypical neuroleptics: A new approach in the treatment of negative symptoms
106. Meta-analysis of amisulpride-a selective dopamine receptor antagonist with an 'atypical' profile
107. Antipsychotic induced weight gain; a comprehensive research synthesis
108. Overview: Maintenance therapy in psychiatry, I: Schizophrenia
109. Treatment programme and long-term outcome in chronic schizophrenia
110. Schizophrenia